Recent studies suggest that copy number variants (CNVs) may contribute to the missing heritability of complex diseases such as Alzheimer's disease (AD) and related dementias (ADRD). We performed a CNV analysis using genotyping data (Axiom 815 K Spanish biobank array) from the GR@ACE/DEGESCO dementia dataset (n = 20,067) of the Spanish population. Applying PennCNV and extensive quality control, 8275 controls and 7818 dementia cases were selected for gene-level case/control associations. We identified 43,833 CNVs with deletions (47%) and duplications (53%). No genome-wide significant associations were found, but nominal associations were observed in PKP3-SIGIRR and FBRSL1 loci. CNVs in 2970 genes were exclusive to dementia cases and enriched in vascular-related pathways. Notable findings included 14q11.2 duplication and VPS13B deletions in ADRD cases, the latter confirmed by optical genome mapping. Our findings suggest potential novel genes associated with ADRD in the Spanish population. However, the limited resolution of array-based technologies in detecting CNVs warrants further investigation.
Alzheimer’s disease (AD) is the leading cause of dementia in the aging population, with the ε4 allele of apolipoprotein E ( APOE ) being the strongest genetic risk factor. Although astrocytes are a major source of APOE, how APOE alleles affect astrocyte maturation and function remains unclear. We generated human induced pluripotent stem cell (hiPSC)-derived astrocytes from AD patients carrying ε3/ε3 and ε4/ε4 alleles and from healthy controls (HC). We also used isogenic gene-edited hiPSC lines homozygous for each APOE allele and an APOE knock-out line to identify allele-specific phenotypes and distinguish gain- from loss-of-function mechanisms. APOE 4/4 astrocyte cultures showed significant reductions in GFAP- and S100β-positive cell percentages compared to APOE 2/2 and APOE 3/3, with no changes in GLT-1- and AQP4-positive cells. Astrocytes of all genotypes responded to IL-1β + TNFα by increasing proinflammatory cytokine expression and release, and to both IL-1β + TNFα and Aβ1-42 by changing morphology, with APOE 4/4 astrocytes showing increased IL6 mRNA and morphological branching upon IL-1β + TNFα stimulation. Notably, under basal conditions, APOE 4/4 astrocytes showed significant reductions in glutamate uptake capacity and cell size alongside increased IL-6 release and CXCL3 mRNA expression. In Aβ1-42 uptake experiments, the proportion of Aβ+astrocytes was higher in APOE 4/4 than in APOE KO cultures. Most phenotypes were absent in APOE KO astrocytes, suggesting that the effects of APOE 4/4 were predominantly mediated through gain-of-function mechanisms. Our results indicate that APOE 4/4 alters astrocyte morphological and molecular maturation while promoting inflammation, disturbing glutamate and Aβ handling under basal conditions. It suggests that APOE ε4/ε4 genotype disrupts astrocyte development and key processes of cellular homeostasis early in Alzheimer’s disease etiopathology. ### Competing Interest Statement The authors have declared no competing interest. Agencia Estatal de Investigación, SAF2016-80419-R, PID2019-109059RB-I00, PID2022-137076OB-I00, PID2022-143181OB100, PID2021-122586NB-I00, PID2024-156577NB-I00 Instituto de Salud Carlos III, https://ror.org/00ca2c886, CIBERNED CB06/05/065, CIBERNED CB06/05/055, CIBERNED PI2013/01, CIBERNED PI2015-2 European Union, ADAPTED, grant agreement 115975-2, AND-PD, Grant Agreement No. 84800 European Regional Development Fund (ERDF)
Astrocytes play essential roles in neuropathology. Human astrocytes exhibit unique properties, highlighting the importance of studying astrocytic responses in human models. Varicose projection astrocytes, previously considered exclusive to hominoids and a physiological type of astrocytes, were suggested to reflect pathological burden, albeit direct evidence linking them to neurological diseases has been lacking. Here, we demonstrate that varicose projection astrocytes also appear in other mammals and show, from four distinct human-based disease models, that varicose projection astrocytes are induced by neuroinflammation and characterized by distinctive subcellular features, indicating involvement in cellular stress responses, and their density is increased in aging and human neuropathology. Our findings establish varicose projection astrocytes as a reactive phenotype associated with neuropathology.
Dysphagia at time of diagnosis suggests atypical parkinsonism instead Parkinson´s disease (PD). Our aim was to analyze the frequency of dysphagia in patients with early PD comparing with a control group and to identify related factors. Patients with early PD (≤ 2 years from symptoms onset) who were recruited from January/2016 to November/2017 (baseline visit; V0) and evaluated annually for 5 years from the Spanish cohort COPPADIS were included in this prospective study. Controls were assessed at baseline and at 2-, 4-, and 5-year follow-up. Dysphagia was defined as a score ≥ 1 in the item 20 of the Non-Motor Symptoms Scale (NMSS). Dysphagia was more frequent at baseline in PD patients (19.6
BACKGROUND AND OBJECTIVE:New device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024. PATIENTS AND METHODS:Data collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included. RESULTS:A total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected. CONCLUSION:Subcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.